Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials

Lignende værker

• Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
  af: Passaro, Antonio, et al.
  Udgivet: (2016)
• Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?
  af: Mitsudomi, Tetsuya, et al.
  Udgivet: (2016)
• Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
  af: Wu, Yi-Long, et al.
  Udgivet: (2018)
• Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
  af: James Chih-Hsin Yang, et al.
  Udgivet: (2022-04-01)
• Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
  af: Schuler, M., et al.
  Udgivet: (2016)